Abu Dhabi Announces Partnership with MSD to Advance Operational Excellence and Expand Access across the Region
ABU DHABI, UAE, June 25, 2026 /PRNewswire/ -- As healthcare systems worldwide seek more resilient and efficient pathways to deliver innovative medicines, the Department of Health – Abu Dhabi (DoH) has announced a collaboration with global...
Translational Research Results of Sacituzumab Tirumotecan (sac-TMT) in Combination with Osimertinib as First-Line Treatment for EGFR-Mutant NSCLC Published in Cancer Cell
— The study shows that EGFR-TKIs induce TROP2 upregulation in DTP cells, providing a mechanistic basis for combining sac-TMT with EGFR-TKI. — The Company is conducting a Phase III registrational study of sac-TMT plus osimertinib as first-line...
Nuance Pharma Announces Publication of Phase 3 ENHANCE-CHINA Data in the CHEST Journal
Ohtuvayre® (ensifentrine) helped improve lung function in Chinese adult patients in in data published in peer reviewed journal SHANGHAI, April 20, 2026 /PRNewswire/ -- Nuance Pharma ("Nuance" or the "Company") announces that CHEST, the official...
Kelun-Biotech Announces Results from the SKB264-II-06/MK-2870-002 Study of Sacituzumab Tirumotecan (Sac-TMT) in Gynecologic Oncology Presented at 2026 SGO
CHENGDU, China, April 14, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) announced that results from both the ovarian cancer cohort and the cervical cancer cohort of Phase II study...
Kelun-Biotech to Present the Final OS Analysis of Sacituzumab Tirumotecan (Sac-TMT) from the OptiTROP-Lung03 Study
CHENGDU, China, March 18, 2026 /PRNewswire/ -- The 2026 European Lung Cancer Congress (ELCC) will be held in Copenhagen, Denmark, from March 25 to 28, 2026 (local time). At this congress, the final OS analysis from the pivotal study...
Nuance Pharma Announces Approval of Ohtuvayre® (ensifentrine) in Hong Kong SAR, China
Approval marks the second regulatory approval outside of the U.S. Food and Drug Administration, further expanding access to COPD patients in select Special Administrative Regions (SARs) in Greater China SHANGHAI, March 12, 2026 /PRNewswire/ --...
Nuance Pharma Announces Acceptance for Review of the New Drug Application for Ohtuvayre® (ensifentrine) by the National Medical Products Administration of China for the maintenance treatment of chronic obstructive pulmonary disease
SHANGHAI, Jan. 27, 2026 /PRNewswire/ -- Nuance Pharma ("Nuance") today announced that the National Medical Products Administration (NMPA) of China has officially accepted for review the New Drug Application (NDA) for Ohtuvayre ® (ensifentrine) for...
SK bioscience, MSD, and Hilleman Laboratories Advance Zaire ebolavirus Vaccine Development with CEPI Funding
CEPI to provide up to USD 30 million to support development of MSD's Zaire ebolavirus vaccine Collaboration addresses manufacturing complexity and cold-chain challenges to improve yield and thermostability Partnership aims to expand affordable and...
Kelun-Biotech Announces Breakthrough Therapy Designation Granted in China for Sacituzumab Tirumotecan (sac-TMT) in Combination with Immunotherapy Pembrolizumab for First-Line Treatment of PD-L1-Positive NSCLC
CHENGDU, China, Jan. 5, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company," 6990.HK) today announced that its TROP2-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT, also...
Agilent and Monash University Malaysia Mark 15-Year Partnership with New BioDiscovery Hub to Drive Regional Biotech Innovation
Collaboration aimed at accelerating R&D in both small- and large-molecule analysis and building high-impact capabilities in fast-growing Asian markets KUALA LUMPUR, Malaysia, Dec. 5, 2025 /PRNewswire/ -- Agilent Technologies Inc. (NYSE: A)...